<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01569516</url>
  </required_header>
  <id_info>
    <org_study_id>CCHY2010L00161-HPAD2</org_study_id>
    <nct_id>NCT01569516</nct_id>
  </id_info>
  <brief_title>Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease</brief_title>
  <official_title>A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changchun Huayang High-tech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Bionovo Medicine Development Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Changchun Huayang High-tech Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and efficacy of
      Octohydroaminoacridine Succinate tablets and find the optimal dose in patients with mild to
      moderate Alzheimer's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is a preliminary assessment of the Octohydroaminoacridine Succinate
      tablets in the treatment of mild to moderate Alzheimer's disease and explore the efficacy and
      safety of the best dose. The 288 patients were randomly assigned to four groups: high dose
      (4mg / time), moderate dose (2mg / time), low dose (1mg / time) and the placebo group,
      including four weeks of the trial screening period following 16 weeks double-blind treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale - Cognitive Subscale</measure>
    <time_frame>20weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinician's Interview Based Impression of Change, plus caregiver input</measure>
    <time_frame>20weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living:Activities of Daily Living Scale（ADL)</measure>
    <time_frame>20weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental behavior: neuropsychiatric questionnaire (NPI)</measure>
    <time_frame>20weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg, tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg,tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4mg,tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 mg, tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octohydroaminoacridine Succinate Tablets</intervention_name>
    <description>1mg, tid</description>
    <arm_group_label>low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octohydroaminoacridine Succinate Tablets</intervention_name>
    <description>1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid</description>
    <arm_group_label>Moderate dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octohydroaminoacridine succinate Tablets</intervention_name>
    <description>1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid</description>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0mg, tid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of probable AD based on DSM-IV and the NINCDS-ADRDA criteria.

          2. Male/female patient aged between 50 and 85.

          3. mild to moderate probable AD ：Middle school or above: 11 ≤MMSE ≤ 25, elementary
             school: 8 ≤ MMSE ≤ 20, illiteracy: 5 ≤ MMSE ≤ 16.

          4. CT or MRI scan excluding another structural brain disease in one year.

          5. Neurologic examination no significant abnormalities.

          6. Hachinski Ischemic Score &lt; 4；Hamilton Depression Scale ≤10. Able to complete the test
             procedure, audio-visual and physical ability to act to complete the neuropsychological
             measure.

          7. Stable chaperone, more than 2 hours a day together with the patient or accumulated
             fewer than 14 hours per week.

          8. Informed consent of the patient (or legal representative) and of the caregiver
             agreeing to take part in the study.

        Exclusion Criteria:

          1. Proven or clinically suspected other type of dementia such as vascular dementia, Lewy
             body dementia, Parkinson's disease, frontotemporal dementia, g - Jakob disease
             (spastic pseudo-sclerosis), normal pressure hydrocephalus etc.

          2. Sudden onset of early dementia or with gait disorders, seizures and behavioral
             changes.

          3. Clinical manifestations of focal neurological signs (hemiparesis, sensory loss, visual
             field defect) or early extrapyramidal tract signs.

          4. History of cerebrovascular disease and stroke.

          5. Serious lack of folic acid and VitB12, syphilis antibody positive or thyroid
             dysfunction.

          6. Mechanical intestinal obstruction patient ,Resting pulse less than 60,Severe liver or
             renal disease.

          7. Patients with mechanical intestinal obstruction.

          8. History of bone marrow transplantation.Mental illness, such as severe depression.

          9. Cognitive damage caused by alcohol or drug abuse. Disable to correctly evaluate the
             cognitive function.

         10. Critical condition, disable to make the exact evaluation of the efficacy and safety of
             new drug.

         11. Use of any agent for the treatment of dementia within 4 weeks of randomization.

         12. Be sensitive to ACHEI.

         13. Be sensitive to two or more foods/drugs.

         14. Use of another investigational agent within one months of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shifu Xiao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huafang Li, MD</last_name>
    <phone>86-21-64387250</phone>
    <phone_ext>3128</phone_ext>
    <email>lhlh5@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangzhou Brain Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Li</last_name>
      <phone>86-20-81898313</phone>
    </contact>
    <investigator>
      <last_name>Muni Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guilin Medical University</name>
      <address>
        <city>Guilin</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Chen</last_name>
      <phone>86-13737710329</phone>
      <email>glfyli@163.com</email>
    </contact>
    <investigator>
      <last_name>Kaixiang Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei mental health center</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qinpu Jiang</last_name>
      <email>JiangQinpu@yahoo.cn</email>
    </contact>
    <investigator>
      <last_name>Qinpu Jiang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianping Li</last_name>
      <phone>86-25-68136221</phone>
      <email>jsphkj@163.com</email>
    </contact>
    <investigator>
      <last_name>Weixian Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first Affiliated Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Wang</last_name>
      <phone>13500815780</phone>
    </contact>
    <investigator>
      <last_name>Li Sun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Qin</last_name>
      <email>qinjian3337@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yan Bai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Medical School of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benyan Luo</last_name>
      <email>luobenyan@zju.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Min Tang</last_name>
      <email>tangmintj@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Benyan Luo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing HuiLongGuan Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guanghui Zhang</last_name>
      <email>zhgh1998@126.com</email>
    </contact>
    <investigator>
      <last_name>Lan Shang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital, EMU</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shumei Wang</last_name>
      <email>13811830809@126.com</email>
    </contact>
    <investigator>
      <last_name>Jing Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongxin Zhao, MD</last_name>
      <email>zhaozx@medmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Liuqing Huang, MD</last_name>
      <email>huangliuqing2008@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhongxin Zhao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liuqing Huang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohua Li</last_name>
      <phone>86-21-63240090</phone>
      <phone_ext>6410</phone_ext>
    </contact>
    <investigator>
      <last_name>Xiaoping Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Tenth People's hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Yu</last_name>
    </contact>
    <investigator>
      <last_name>Xueyuan Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huafang Li</last_name>
      <phone>86-21-64387250</phone>
      <phone_ext>3128</phone_ext>
      <email>Lhly5@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Shifu Xiao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xia Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2012</study_first_posted>
  <last_update_submitted>April 6, 2012</last_update_submitted>
  <last_update_submitted_qc>April 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Octohydroaminoacridine Succinate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

